Short and Mid Term Outcomes of Cryopreserved Abdominal Aortic Allografts Used as a Substitute for Infected Prosthetic Grafts in 200 Patients.


Journal

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
ISSN: 1532-2165
Titre abrégé: Eur J Vasc Endovasc Surg
Pays: England
ID NLM: 9512728

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 24 07 2020
revised: 17 02 2021
accepted: 20 02 2021
pubmed: 17 4 2021
medline: 21 8 2021
entrez: 16 4 2021
Statut: ppublish

Résumé

To investigate the use of cryopreserved arterial allografts (CAA) as a substitute for infected infrarenal aortic prostheses, and its outcomes. A single centre retrospective study of consecutive patients receiving an abdominal aortic CAA after removal of an infected graft was conducted between January 1997 and December 2013. The primary outcome was the rate of allograft related revision surgery. Secondary outcomes were the 30 day mortality rate, survival, primary patency, limb salvage, and infection recurrence. Allograft ruptures secondary to infection and risk factors for allograft failure were also investigated. Two hundred patients (mean age 64.2 ± 9.4 years) were included. In 56 (28%) cases, infection was related to an enteric fistula. The mean follow up duration was 4.1 years. The 30 day mortality rate was 11%. Early revision surgery was needed in 59 patients (29.5%). Among them, 15 (7.5%) were allograft related and led to the death of three patients (1.5%), corresponding to a 7.5% 30 day allograft related revision surgery rate. During the first six months, 17 (8.5%) patients experienced 21 events with complete or partial rupture (pseudo-aneurysm) of the allograft responsible for five (2.5%) deaths, corresponding to a re-infection rate of 8.5%. The multivariable analysis showed that diabetes and pseudo-aneurysm of the native aorta on presentation were predictive factors for short term allograft rupture. After six months, 25 (12.5%) patients experienced long term allograft complications (rupture, n = 2, 1%; pseudo-aneurysm, n = 6, 3%; aneurysm, n = 2, 1%; thrombosis, n = 11, 5.5%; stenosis, n = 4, 2%;) requiring revision surgery resulting in one death. The five year rates of survival, allograft related revision surgery, limb salvage, primary patency, and infection recurrence were 56%, 30%, 89%, 80%, and 12%, respectively. CAAs provide acceptable results to treat aortic graft infection with few early graft related fatal complications. Long term allograft related complications are quite common but are associated with low mortality and amputation rates.

Identifiants

pubmed: 33858752
pii: S1078-5884(21)00188-X
doi: 10.1016/j.ejvs.2021.02.036
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

89-97

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.

Auteurs

Thibault Couture (T)

Sorbonne Université, Department of Vascular Surgery, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, France.

Julien Gaudric (J)

Sorbonne Université, Department of Vascular Surgery, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, France. Electronic address: julien.gaudric@aphp.fr.

Sophie Tezenas Du Montcel (ST)

Biostatistics Department, Sorbonne Université, Pitié-Salpêtrière Hospital, UMR_S1136; INSERM UMR_S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.

Jérémie Jayet (J)

Sorbonne Université, Department of Vascular Surgery, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, France.

Dorian Verscheure (D)

Sorbonne Université, Department of Vascular Surgery, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, France.

Jean Michel Davaine (JM)

Sorbonne Université, Department of Vascular Surgery, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, France.

Mohamed Jarraya (M)

Université de Paris, Human Tissue Bank, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, France.

Laurent Chiche (L)

Sorbonne Université, Department of Vascular Surgery, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, France.

Fabien Koskas (F)

Sorbonne Université, Department of Vascular Surgery, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH